Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

MAB Discovery GmbH. (4/5/18). "Press Release: EUROSTARS Grants Project Funding for SPARKLE Consortium". Neuried.

Region Region EU (European Union)
Organisations Organisation MAB Discovery GmbH
  Organisation 2 MC Services AG
Products Product antibiotic
  Product 2 drug discovery technology
Persons Person Fischer, Stephan (MAB Discovery GmbH 201209 Managing Director + Founder)
  Person 2 Riedl, Claudia (Gutjahr-Löser) (MC Services 201710– Managing Director before MorphoSys 2002–2017 + Cassiopeia + DB)

- MAB Discovery technology will be employed for selection and development of therapeutic antibodies against drug-resistant Klebsiella pneumoniae

MAB Discovery GmbH is part of the SPARKLE consortium of five partners which receives 36 months funding from the EUSTARS program ( The unique MAB Discovery technology platform for the generation of novel monoclonal antibody drugs will be applied to pave the way for innovative treatments of severe infections by multidrug resistant bacteria.

The consortium will develop and perform the preclinical validation of an innovative therapeutic strategy against antibiotic-resistant Klebsiella pneumoniae (ARKP) infections. Klebsiella pneumoniae (KP) is a common hospital-acquired pathogen for which, due to resistance, treatment options are very limited. The therapy is based on a therapeutic monoclonal antibody (mAb) that specifically targets ARKP. Upon completion of the project, the mAb product will be ready for further clinical development.

"We are dedicated to deliver a set of novel molecules for the treatment and cure of severe infections. Being a part of the SPARKLE consortium broadens the scope of applications and underscores again the high performance of our rabbit-based antibody discovery platform," said Dr. Stephan Fischer, CEO of MAB Discovery.

MAB Discovery delivers high quality, functional monoclonal antibodies via sophisticated, high-throughput selection of B cells generated by immunization and delivers a vast number of high quality candidates with regard to potency and epitope coverage. The use of wild type rabbits for immunization and the functional B-cell cloning strategy of MAB Discovery suits not only classical target proteins and receptors, but also to a wide variety of more challenging immunogens.

About MAB Discovery

Founded in 2010 by Dr. Stephan Fischer, MAB Discovery utilizes a unique rabbit-based antibody discovery platform to develop high quality, functional monoclonal antibodies targeting traditional proteins and receptors as well as a wide variety of more challenging immunogens such as GPCRs and ion channels. The MAB Discovery team has extensive experience in developing antibody-based therapeutics having worked together at Roche Biologicals for several years. The company follows a flexible collaboration-based business model to meet the needs of its clients and ongoing partners. For additional information, please visit


MAB Discovery:
Stephan Fischer
+49 89 990 178-0

For media inquiries:
MC Services AG
Dr. Claudia Gutjahr-Löser
+49 89 210 228-0

Record changed: 2018-04-16


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for MAB Discovery GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top